Optimer Pharmaceuticals Reports Third Quarter 2009 Financi... (h submissions will be accepted or approv...)

Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results

Date:11/3/2009

h submissions will be accepted or approved, Optimer's ability to enter into partnerships on favorable terms or at all, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

    Contacts

    Optimer Pharmaceuticals, Inc.
    John Prunty, CFO & VP, Finance
    Christina Donaghy, Corporate Communications Manager
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005

Optimer Pharmaceuticals, Inc.
Consolidated Statements of Operations
(unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
------------- -------------
2009 2008 2009 2008
---- ---- ---- ----
Revenues:
Research grants $176,202 $239,212 $583,992 $844,675
Collaborative
research
agreements - - 100,000 50,000
--- --- ------- ------
Total revenues 176,202 239,212 683,992 894,675
Operating expenses:
Research and
development 7,192,383 7,877,906 26,519,447 21,003,764
Marketing 393,864 415,916 1,179,212 1,695,400
General and
administrative 2,030,137 1,544,925 5,949,946 4,803,422
--------- --------- --------- ---------
Total operating
expenses 9,616,384 9,838,747 33,648,605 27,502,586
--------- --------- ---------- ----------
Loss from
operations (9,440,182) (9,599,535) (32,964,613) (26,607,911)

'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved
0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009

Post Your Comments:

Optimer Pharmaceuticals Reports Third Quarter 2009 Financi...(h submissions will be accepted or approv...)